← ANALYST RATINGS · TIPRANKS
Glaukos (GKOS): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy1 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $198, the highest $225, the lowest $172. The average is +19.9% from the last price of $165.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $190 | Buy | +15.3% | Reiterated | 16.10.26on TipRanks 08:08 | +0.6% | ↗ |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $185 | Buy | +12.2% | Assigned | 13.10.26on TipRanks 07:35 | −1.5%next day +2.5% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $202 → $205+1.5% | Buy | +24.4% | Reiterated | 12.10.26on TipRanks 08:35 | +1.5%next day −1.5% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $195 | Buy | +18.3% | Reiterated | 12.10.26on TipRanks 07:45 | +1.5%next day −1.5% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $195 | Buy | +18.3% | Reiterated | 08.10.26on TipRanks 07:07 | −5.9%next day +2.1% · 5 days +2.9% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $202 | Buy | +22.5% | Reiterated | 06.10.26on TipRanks 06:50 | −2.0%next day +6.8% · 5 days +2.6% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $190 | Buy | +15.3% | Reiterated | 02.10.26on TipRanks 09:15 | −0.4%next day −0.5% · 5 days 0.0% | ↗ |
| Michael Sarcone★★★★★★★★★★#4693 · hits 45% · avg +6.5% | Jefferies | $210 | Buy | +27.4% | Reiterated | 22.09.26on TipRanks 08:35 | −1.0%next day −3.3% · 5 days +0.4% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $190 | Buy | +15.3% | Reiterated | 04.09.26on TipRanks 09:35 | −1.2%next day +4.8% · 5 days −2.4% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $193 → $202+4.7% | Buy | +22.5% | Assigned | 20.08.26on TipRanks 07:30 | −1.6%next day −0.4% · 5 days −2.7% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $188 → $225+19.7% | Buy | +36.5% | Reiterated | 14.08.26on TipRanks Aug 13 12:15 | +0.8%next day −2.4% · 5 days −0.4% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $165 → $195+18.2% | Buy | +18.3% | Reiterated | 07.08.26on TipRanks 11:27 | +4.7%next day +0.8% · 5 days +2.1% | ↗ |
| Allen Gong★★★★★★★★★★#2251 · hits 46% · avg +14.7% | J.P. Morgan | $200 | Buy | +21.3% | Reiterated | 04.08.26on TipRanks Aug 5 08:08 | −2.0%next day +0.4% · 5 days +6.8% | ↗ |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $170 → $190+11.8% | Buy | +15.3% | Reiterated | 04.08.26on TipRanks 06:07 | — | |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $161 → $187+16.1% | Hold | +13.4% | Downgrade | 04.08.26on TipRanks 06:07 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $159 → $176+10.7% | Hold | +6.8% | Reiterated | 04.08.26on TipRanks 06:07 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $174 → $184+5.7% | Hold | +11.6% | Reiterated | 04.08.26on TipRanks 06:07 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $157 → $180+14.6% | Hold | +9.2% | Reiterated | 04.08.26on TipRanks 06:07 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $162 → $179+10.5% | Hold | +8.6% | Reiterated | 04.08.26on TipRanks 06:07 | — | |
| Anthony Petrone★★★★★★★★★★#1225 · hits 54% · avg +8.5% | Mizuho Securities | $185 | Buy | +12.2% | Reiterated | 31.07.26on TipRanks Aug 4 08:18 | −1.8%next day +1.1% · 5 days +4.5% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $168 → $195+16.1% | Buy | +18.3% | Reiterated | 30.07.26on TipRanks 12:59 | +2.6%next day −1.8% · 5 days −2.2% | ↗ |
| Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% | Truist Financial | $180 → $215+19.4% | Buy | +30.4% | Reiterated | 30.07.26on TipRanks 07:56 | +2.6%next day −1.8% · 5 days −2.2% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 30.07.26on TipRanks 06:45 | +2.6%next day −1.8% · 5 days −2.2% | ↗ |
| Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% | Wells Fargo | $138 → $178+29.0% | Buy | +8.0% | Assigned | 30.07.26on TipRanks 06:30 | +2.6%next day −1.8% · 5 days −2.2% | ↗ |
| David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% | Needham | $150 → $201+34.0% | Buy | +21.9% | Reiterated | 30.07.26on TipRanks 06:30 | +2.6%next day −1.8% · 5 days −2.2% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $150 → $172+14.7% | Hold | +4.3% | Reiterated | 30.07.26on TipRanks Jul 28 08:15 | −0.6%next day +8.4% · 5 days +8.6% | ↗ |
| David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% | Goldman Sachs | $153 | Buy | −7.2% | Reiterated | 25.05.26on TipRanks May 26 07:50 | −5.0%next day −4.4% · 5 days −4.8% | ↗ |
| Mason Carrico★★★★★★★★★★#10833 · hits 38% · avg −4.7% | Stephens | $115 → $145+26.1% | Buy | −12.0% | Reiterated | 02.01.26on TipRanks 07:15 | −2.1%next day +1.0% · 5 days +0.4% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Glaukos
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $197 at a price of $164 (+20.2%); now: $198 at $165 (+19.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Buy | 24 | 32 | 38 | 32 | 24 | 13 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.18 to $-0.03). Last quarter: $-0.14.
Sales
Next quarter’s sales estimate — $168M (from $160M to $174M). Last quarter: $186M.
Best top-analyst consensus in the sector · Healthcare
About Glaukos
- CEO: Thomas William Burns
- Employees: 1,094
- One Glaukos Way, Aliso Viejo, CA, 92656, US
- www.glaukos.com
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗